CAN Health Network and Quebec-Based DIAGNOS Announce Life-Changing Diabetic Retinopathy Screening Program Partnership
March 15 2022 - 2:00PM
The Coordinated Accessible National (CAN) Health Network is excited
to announce that leading vision care company, DIAGNOS, is the first
Quebec-based organization to join the Network. Through their
strategic partner, Labtician Ophthalmics Inc, a Toronto-based
company with Eyecare Specialist customers across Canada, DIAGNOS’
CARA solution will help health care professionals in their
day-to-day screening of diabetic patients by allowing them to
monitor ocular health, ultimately helping to prevent vision loss in
their patients.
Diabetic Retinopathy is the leading cause of blindness, and
early detection has been identified as the best preventative
measure and solution. Patients who require these critical
screenings often come up against barriers resulting in
non-compliance, high costs, or a missed diagnosis, leading to
potentially life-altering vision loss. In particular, DIAGNOS’
solution will help professionals identify patients who are overdue
for a screening, ensuring Diabetic Retinopathy is caught early.
This low-cost, non-invasive state-of-the-art technology involves
the use of a simple rear eye camera image, which quickly and
effectively screens patients. Assessment results are then returned
within a few minutes; saving both time and health care costs.
“DIAGNOS, a publicly traded company on the TSX Venture Exchange,
is pleased to be part of the CAN-Health Network,” said André
Larente, CEO, DIAGNOS. “Our solution for screening diabetic
patients uses Artificial Intelligence. The CARA application is
approved by Health Canada and is in use today in hospitals and
primary care clinics. This new local screening program will give
accessibility to all patients in Canada to a fast and low priced
medical test.”
Funded by Government of Canada, the CAN Health Network works
with health care providers to identify their biggest challenges,
and matches them with Canadian-made technology solutions. This
Integrated Market model allows Canadian innovators to gain access
to the healthcare market, and rapidly validate and scale their
solution across the country, and internationally.
“The CAN Health Network has been focused on accessing the Quebec
marketplace to ensure a truly national scope and economic
prosperity for all of Canada. Adding DIAGNOS and Labtician to the
Network is another great step in ensuring all Canadians have access
to the best home-grown innovative health care technologies,” said
Dante Morra, Chair, CAN Health Network.
“We are pleased to be working with CAN Health Network and
DIAGNOS, a Canadian company based in Quebec, in addressing growing
needs in the monitoring of diabetic patients,” explains Labtician
President, Polydor Strouthos. “For over 60 years, we’ve been
introducing innovative eye care products, solutions, and resources
for eyecare professionals and their patients in the Canadian
marketplace. Through our extensive network, we commercialize our
high-quality value add eyecare products as well as those of our
forward-thinking partner companies in Canada and worldwide. We help
companies through the complexities and nuances of Canadian and
international markets, from prelaunch assistance and obtaining
regulatory approval, to securing commercialization, and
distribution channels.”
ASSOCIATED LINKS
- Government of Canada provides more
support to CAN Health Network
- DIAGNOS
- www.labtician.com
ABOUT DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to
early detection of critical health problems based of its FLAIRE
Artificial Intelligence (AI) platform. FLAIRE allows for quick
modifying and developing of applications such as CARA (Computer
Assisted Retina Analysis). CARA’s AI-based image enhancement
algorithms provide sharper, clearer and easier-to-analyze retinal
images. CARA is a cost-effective tool for real-time screening of
large volumes of patients. CARA has been cleared for
commercialization by the following regulators: Health Canada, the
FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi
Arabia). DIAGNOS works with AI Distributor, Labtician Ophthalmics
(Labtician).
ABOUT CAN HEALTH The CAN Health Network is a
Canada-first approach to technology adoption. It helps break down
barriers to scaling in the health care system and provides an
environment for companies to scale to their full potential.
Currently operating in Ontario, Western and Atlantic Canada, the
CAN Health Network will soon be expanding into Quebec and the
North. The Network has received a total of $12.45 million in
funding from the Government of Canada to build a national platform
that harnesses the purchasing power of health care organizations.
To learn more about the CAN Health Network, visit
canhealthnetwork.ca.
For more information:
Mr. Polydor Strouthos, President
Labtician Ophthalmics Inc.
Tel: 905-829-0055 ext. 227
pstrouthos@labtician.com
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Natasha Zelinski, Communications Coordinator
CAN Health Network
natasha.zelinski@thp.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Aug 2023 to Aug 2024